Organising Research and Development for Evidence-informed Health Care: Some Universal Characteristics and a Case Study from the UK

Overview

Journal Health Econ Policy Law

Publisher Cambridge University Press

Specialty Public Health

Date 2021 Apr 12

PMID 33843559

Authors

Anthony J Culyer

Kalipso Chalkidou

Affiliations

Soon will be listed here.

Abstract

Research and Development (R&D) in health and health care has several intriguing characteristics which, separately and in combination, have significant implications for the ways in which it is organised, funded and managed. We review the characteristics, some of which apply under most circumstances and others of which may be context-specific, explore their implications for the organisation and management of health-related R&D, and illustrate the main features from the UK experience in the 1990s.

References

Chalkley M, Khalil F . Third party purchasing of health services: patient choice and agency. J Health Econ. 2005; 24(6):1132-53. DOI: 10.1016/j.jhealeco.2005.04.002. View

Isaranuwatchai W, Li R, Glassman A, Teerawattananon Y, Culye A, Chalkidou K . Disease Control Priorities Third Edition: Time to Put a Theory of Change Into Practice Comment on "Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy". Int J Health Policy Manag. 2019; 8(2):132-135. PMC: 6462203. DOI: 10.15171/ijhpm.2018.115. View

Atkinson P, Sheard S, Walley T . 'All the stars were aligned'? The origins of England's National Institute for Health Research. Health Res Policy Syst. 2019; 17(1):95. PMC: 6894247. DOI: 10.1186/s12961-019-0491-5. View

Chalkidou K, Li R, Culyer A, Glassman A, Hofman K, Teerawattananon Y . Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness". Int J Health Policy Manag. 2017; 6(4):233-236. PMC: 5384986. DOI: 10.15171/ijhpm.2016.118. View

Culyer A . Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context. Pharmacoeconomics. 2010; 28(10):889-97. DOI: 10.2165/11535270-000000000-00000. View

Culyer A, Chalkidou K, Teerawattananon Y, Santatiwongchai B . Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?. F1000Res. 2018; 7:72. PMC: 5961761. DOI: 10.12688/f1000research.13284.1. View

Peckham M . Research and development for the National Health Service. Lancet. 1991; 338(8763):367-71. DOI: 10.1016/0140-6736(91)90494-a. View

Butler J . Hospital cost analysis. Dev Health Econ Public Policy. 1994; 3:vii-xxii, 1-393. View

Dranove D, White W . Agency and the organization of health care delivery. Inquiry. 1987; 24(4):405-15. View

10.

Culyer A, Chalkidou K . Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?. Value Health. 2019; 22(1):99-103. PMC: 6347566. DOI: 10.1016/j.jval.2018.06.005. View

11.

Harper G, Townsend J, Buxton M . The preliminary economic evaluation of health technologies for the prioritization of health technology assessments. A discussion. Int J Technol Assess Health Care. 1999; 14(4):652-62. DOI: 10.1017/s026646230001196x. View

12.

Culyer A . Supporting research and development in the National Health Service. Report of a meeting of the 1942 club, January 1995. The recommendations. J R Coll Physicians Lond. 1995; 29(3):216-24. PMC: 5401176. View

13.

Goddard M, Mannion R, Smith P . Enhancing performance in health care: a theoretical perspective on agency and the role of information. Health Econ. 2000; 9(2):95-107. DOI: 10.1002/(sici)1099-1050(200003)9:2<95::aid-hec488>3.0.co;2-a. View

14.

Hauck K, Morton A, Chalkidou K, Chi Y, Culyer A, Levin C . How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations. Soc Sci Med. 2018; 220:141-149. PMC: 6323413. DOI: 10.1016/j.socscimed.2018.10.030. View

15.

Norman R, Chalkidou K, Culyer A . A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making. Value Health. 2018; 21(2):117-118. DOI: 10.1016/j.jval.2017.12.005. View

16.

Labelle R, Stoddart G, Rice T . A re-examination of the meaning and importance of supplier-induced demand. J Health Econ. 1994; 13(3):347-68. DOI: 10.1016/0167-6296(94)90036-1. View

17.

Townsend J, Buxton M . Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy. Health Policy. 1997; 39(3):181-94. DOI: 10.1016/s0168-8510(96)00870-6. View

18.

Eddy D . Selecting technologies for assessment. Int J Technol Assess Health Care. 1989; 5(4):485-501. DOI: 10.1017/s0266462300008424. View

19.

Hanney S, Kuruvilla S, Soper B, Mays N . Who needs what from a national health research system: lessons from reforms to the English Department of Health's R&D system. Health Res Policy Syst. 2010; 8:11. PMC: 2881918. DOI: 10.1186/1478-4505-8-11. View

20.

Drummond M, Davies L, Ferris 3rd F . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Soc Sci Med. 1992; 34(9):973-81. DOI: 10.1016/0277-9536(92)90128-d. View